Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

4,803 total articles

Why Apple’s Leadership Reset Keeps the Bull Case Intact

Why Apple’s Leadership Reset Keeps the Bull Case Intact

Apple’s recent leadership changes look like continuity by another name: experienced insiders, an intact product roadmap and a capital return engine that keeps investors comfortable. This trade idea targets a measured long exposure with defined risk limits — capture upside from product and services momentum while protecting against execution and reg…

First Quantum: A Copper Upside Trade Backed by a Re-rating Catalyst

First Quantum: A Copper Upside Trade Backed by a Re-rating Catalyst

First Quantum Minerals (FQVLF) is a large copper producer ($22.5B market cap) trading well above 2025 lows but still below its January highs. A combination of improving copper fundamentals, operational resets, and an active short base creates an asymmetric swing trade. This idea lays out a specific entry, stop and target with horizon and risk contr…

Perma-Pipe Pullback: A Tactical Re-entry on Stabilizing Fundamentals

Perma-Pipe Pullback: A Tactical Re-entry on Stabilizing Fundamentals

Perma-Pipe (PPIH) has retraced from its 52-week high and is trading at a more attractive entry after strong backlog and Q1 recovery. Fundamentals show improving profitability (trailing EPS $2.10, ROE ~18.8%) and a modest leverage profile. This trade idea presents a measured long with defined entry, stop and target tailored to a mid-term horizon.

Zions: NII Momentum + Buyback = Re-rating Opportunity into 2026

Zions: NII Momentum + Buyback = Re-rating Opportunity into 2026

Zions Bancorporation is showing the building blocks for a 2026 re-rating: rising yields should lift net interest income, recent corporate actions (a $75M repurchase and steady dividend) support per-share cash flow, and the stock trades at a modest P/E and low P/B. We lay out a long trade with entry at $62.00, stop at $57.00 and a primary target of …

Intuitive Machines: Buy the Moon-Infra Transition, Trim at Proof Points

Intuitive Machines: Buy the Moon-Infra Transition, Trim at Proof Points

Intuitive Machines (LUNR) is trading near $28.41 after a run from a $6.75 52-week low as investor focus shifts from a single lunar mission to recurring cislunar services. The company shows early revenue upside via government and commercial lunar contracts (including a $180.4 million award), strong liquidity per share, but valuation metrics (P/S ~20…

Bright Horizons: Re-Rating Setup as Macro and Fundamentals Align

Bright Horizons: Re-Rating Setup as Macro and Fundamentals Align

Bright Horizons (BFAM) looks positioned for a re-rating. At roughly $85, the stock trades at ~24x earnings with $258M in trailing free cash flow and an enterprise value near $5.5B. Improving technicals, manageable leverage and reopening tailwinds create a clear risk-reward for a mid-term trade targeting $110 over the next 45 trading days, with a $7…

Spotify 2.0: From Streaming App to Data-Driven Growth Platform

Spotify 2.0: From Streaming App to Data-Driven Growth Platform

Spotify has shifted from pure music streaming to a data-rich platform that can monetize podcasts, video, and personalized ad formats. Recent earnings and product moves suggest durable margin expansion and an accelerating monetization runway. This trade uses a measured long entry with a clear stop and a 180-trading-day target to capture the next leg…

EQBK: Undervalued Regional Bank Setup With Asymmetric Upside

EQBK: Undervalued Regional Bank Setup With Asymmetric Upside

Equity Bancshares (EQBK) looks like a pragmatic buy here: the stock sits below $1 billion market cap, generates meaningful free cash flow, and has a recent history of earnings beats and targeted M&A. Valuation metrics are not demanding on a price-to-book basis, short interest is elevated, and technicals are neutral-to-bullish. This trade lays out a…

BridgeBio: Optionality From Rare-Disease Revenues to a KRAS Play

BridgeBio: Optionality From Rare-Disease Revenues to a KRAS Play

BridgeBio (BBIO) is staging a transition from a pure rare-disease developer to a commercial-stage company with optionality for oncology expansion. Recent wins (Attruby long-term mortality data, positive BBP-418 Phase 3 readout, achondroplasia data) should drive revenue and M&A firepower that could be redeployed into KRAS-targeted assets or partners…